Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.

× No keyword cloud information.

6 in total

Review 1. Lifelong TKI therapy: how to manage cardiovascular and other risks.

Authors: Michael J Mauro
Journal: Hematology Am Soc Hematol Educ Program Date: 2021-12-10

2. ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Authors: Dongqing Yan; Anthony D Pomicter; Thomas O'Hare; Michael W Deininger
Journal: Clin Cancer Res Date: 2019-09-20 Impact factor: 12.531

Review 3. Treatment-free remission in patients with chronic myeloid leukaemia.

Authors: David M Ross; Timothy P Hughes
Journal: Nat Rev Clin Oncol Date: 2020-05-06 Impact factor: 66.675

4. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.

Authors: Jerald P Radich; Andreas Hochhaus; Tamás Masszi; Andrzej Hellmann; Jesper Stentoft; María Teresa Gómez Casares; J Valentín García-Gutiérrez; Eibhlin Conneally; Philipp D le Coutre; Norbert Gattermann; Bruno Martino; Susanne Saussele; Francis J Giles; David M Ross; Paola Aimone; Sai Li; Ksenia Titorenko; Giuseppe Saglio
Journal: Leukemia Date: 2021-03-11 Impact factor: 12.883

Review 5. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.

Authors: Richard E Clark
Journal: Curr Hematol Malig Rep Date: 2019-12 Impact factor: 3.952

Review 6. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.

Authors: Elena Inzoli; Andrea Aroldi; Rocco Piazza; Carlo Gambacorti-Passerini
Journal: Am J Hematol Date: 2022-04-12 Impact factor: 13.265

6 in total